

# FIRST LIGHT 14 September 2020

### **RESEARCH**

# **BOB Economics Research | IIP**

IIP improves further

# **SUMMARY**

# India Economics: IIP

India's industrial output declined by 10.4% in Jul'20 as against a decline of 15.8% in Jun'20. Higher capital and durable goods production drove the recovery. FMCG output registered second consecutive month of positive growth, albeit marginally lower than last month. Broader economic activity continues to improve as seen in domestic and global manufacturing PMIs, E-Way bills and domestic vehicle output. However, rising domestic COVID-19 cases remains a key risk to recovery in economic output.

# Click here for the full report.

# **TOP PICKS**

### **LARGE-CAP IDEAS**

Company	Rating	Target
Bajaj Finance	Buy	4,000
<u>Cipla</u>	Buy	850
GAIL	Buy	155
Petronet LNG	Buy	310
Tech Mahindra	Buy	910

### **MID-CAP IDEAS**

Company	Rating Target	
Alkem Labs	Buy	3,600
Chola Investment	Buy	280
<u>Laurus Labs</u>	Buy	1,200
Transport Corp	Buy	270
Mahanagar Gas	Sell	750

Source: BOBCAPS Research

### **DAILY MACRO INDICATORS**

Current	2D (%)	1M (%)	12M (%)
0.68	(2bps)	10bps	(109bps)
6.05	6Ьрѕ	20bps	(62bps)
73.46	0.1	1.9	(3.3)
40.06	(1.8)	(11.0)	(33.7)
27,535	(1.5)	(0.9)	1.3
3,235	(0.6)	(4.3)	6.7
38,840	1.7	1.7	4.7
9 Sep	MTD	CYTD	FYTD
65.2	221.6	(14,868.4)	(5,108.9)
(130.3)	(280.7)	4,526.7	11,129.6
	0.68 6.05 73.46 40.06 27,535 3,235 38,840 9 Sep 65.2	Current (%)  0.68 (2bps)  6.05 6bps  73.46 0.1  40.06 (1.8)  27,535 (1.5)  3,235 (0.6)  38,840 1.7  9 Sep MTD  65.2 221.6	Current         (%)         (%)           0.68         (2bps)         10bps           6.05         6bps         20bps           73.46         0.1         1.9           40.06         (1.8)         (11.0)           27,535         (1.5)         (0.9)           3,235         (0.6)         (4.3)           38,840         1.7         1.7           9 Sep         MTD         CYTD           65.2         221.6 (14,868.4)

Source: Bank of Baroda Economics Research

# **BOBCAPS** Research

research@bobcaps.in





HE

11 September 2020

# IIP improves further

India's industrial output declined by 10.4% in Jul'20 as against a decline of 15.8% in Jun'20. Higher capital and durable goods production drove the recovery. FMCG output registered second consecutive month of positive growth, albeit marginally lower than last month. Broader economic activity continues to improve as seen in domestic and global manufacturing PMIs, E-Way bills and domestic vehicle output. However, rising domestic COVID-19 cases remains a key risk to recovery in economic output.

Sameer Narang
Jahnavi | Sonal Badhan
chief.economist@bankofbaroda.com

IIP on path to recovery: Industrial output contracted by 10.4% in Jul'20 compared with a decline of 15.8% seen in Jun'20. Electricity output now is only 2.5% lower than last year compared with 10% in Jun'20. Mining output is now 13% lower than last year compared with 19.6% decline seen in Jun'20. Manufacturing output too is now 11.1% lower than last year compared with 16% fall seen in Jun'20. We expect further improvement in the coming months given India's manufacturing PMI inched up to 52 in Aug'20 from 46 in Jul'20. During FYTD21, industrial growth is down by 29.2% versus an increase of 3.5% last year.

**Broad based recovery:** Across the board recovery was seen with capital goods output declining at a much slower pace of 22.8% in Jul'20 compared with a decline of 37.4%. So is the case with durable goods which contracted by 23.6% in Jul'20 compared with a decline of 34.3% in Jun'20. Even intermediate and construction goods saw quick recovery with a decline of 12.5% (from 23% in Jun'20) and 10.6% (from 18.8% in Jun'20) respectively. However, growth in FMCG output moderated to 6.7% in Jul'20 from 14.3% in Jun'20, while remaining in the positive territory.

Gradual recovery insight: With the gradual removal of restrictions, an overall pickup in economic activity is visible with high frequency indicators such as e-way bills (contraction of 3.5% in Aug'20 against 7.3% in Jul'20), higher manufacturing PMI (52 in Aug'20 from 46 in Jul'20) and auto production (decline of 5% in Aug'20 against 31% in Jul'20) showing signs of traction. However, uncertainty over COVID-19 vaccine, recent surge in cases and lower general government capex spending remain a downside risk to India's recovery.

### **KEY HIGHLIGHTS**

- IIP growth fell at a slower pace of 10.4% in Jul'20.
- FMCG growth moderated. Capital and consumer durables goods recovered.
- With gradual removal of restrictions, industrial activity will gain momentum.





### Disclaimer

#### Recommendations and Absolute returns (%) over 12 months

BUY - Expected return >+15%

ADD - Expected return from >+5% to +15%

**REDUCE** - Expected return from -5% to +5%

SELL - Expected return <-5%

Note: Recommendation structure changed with effect from 1 January 2018 (Hold rating discontinued and replaced by Add / Reduce)

#### Rating distribution

As of 31 August 2020, out of 100 rated stocks in the BOB Capital Markets Limited (BOBCAPS) coverage universe, 48 have BUY ratings, 21 have ADD ratings, 11 are rated REDUCE and 20 are rated SELL. None of these companies have been investment banking clients in the last 12 months.

#### Analyst certification

Each of the analysts mentioned in this research report certify, with respect to the sections of the report for which they are responsible, that (1) all of the views expressed in this report accurately reflect his/her personal views about the subject company or companies and its or their securities, and (2) no part of his/her compensation was, is, or will be, directly or indirectly, related to the specific recommendation(s) or view(s) in this report. Analysts are not registered as research analysts by FINRA and are not associated persons of BOBCAPS.

#### Important disclosures

This product is a compilation of previously published research notes. To view the complete report along with the associated Analyst certifications and Company-specific disclosures, please click on the hyperlink accompanying each excerpt.

### General disclaimers

BOBCAPS is engaged in the business of Institutional Stock Broking and Investment Banking. BOBCAPS is a member of the National Stock Exchange of India Limited and BSE Limited and is also a SEBI-registered Category I Merchant Banker. BOBCAPS is a wholly owned subsidiary of Bank of Baroda which has its various subsidiaries engaged in the businesses of stock broking, lending, asset management, life insurance, health insurance and wealth management, among others.

BOBCAPS's activities have neither been suspended nor has it defaulted with any stock exchange authority with whom it has been registered in the last five years. BOBCAPS has not been debarred from doing business by any stock exchange or SEBI or any other authority. No disciplinary action has been taken by any regulatory authority against BOBCAPS affecting its equity research analysis activities.

BOBCAPS has obtained registration as a Research Entity under SEBI (Research Analysts) Regulations, 2014, having registration No.: INH000000040 valid till 03 February 2020. BOBCAPS is also a SEBI-registered intermediary for the broking business having SEBI Single Registration Certificate No.: INZ000159332 dated 20 November 2017.

BOBCAPS prohibits its analysts, persons reporting to analysts, and members of their households from maintaining a financial interest in the securities or derivatives of any companies that the analysts cover. Additionally, BOBCAPS prohibits its analysts and persons reporting to analysts from serving as an officer, director, or advisory board member of any companies that the analysts cover.

Our salespeople, traders, and other professionals may provide oral or written market commentary or trading strategies to our clients that reflect opinions contrary to the opinions expressed herein, and our proprietary trading and investing businesses may make investment decisions that are inconsistent with the recommendations expressed herein. In reviewing these materials, you should be aware that any or all of the foregoing, among other things, may give rise to real or potential conflicts of interest. Additionally, other important information regarding our relationships with the company or companies that are the subject of this material is provided herein.

This material should not be construed as an offer to sell or the solicitation of an offer to buy any security in any jurisdiction where such an offer or solicitation would be illegal. We are not soliciting any action based on this material. It is for the general information of BOBCAPS's clients. It does not constitute a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual clients. Before acting on any advice or recommendation in this material, clients should consider whether it is suitable for their particular circumstances and, if necessary, seek professional advice.

The price and value of the investments referred to in this material and the income from them may go down as well as up, and investors may realize losses on any investments. Past performance is not a guide for future performance, future returns are not guaranteed and a loss of original capital may occur. BOBCAPS does not provide tax advice to its clients, and all investors are strongly advised to consult with their tax advisers regarding any potential investment in certain transactions — including those involving futures, options, and other derivatives as well as non-investment-grade securities —that give rise to substantial risk and are not suitable for all investors. The material is based on information that we consider reliable, but we do not represent that it is accurate or complete, and it should not be relied on as such. Opinions expressed are our current opinions as of the date appearing on this material only. We endeavour to update on a reasonable basis the information discussed in this material, but regulatory, compliance, or other reasons may prevent us from doing so.

EQUITY RESEARCH 14 September 2020

#### **FIRST LIGHT**



We and our affiliates, officers, directors, and employees, including persons involved in the preparation or issuance of this material, may from time to time have "long" or "short" positions in, act as principal in, and buy or sell the securities or derivatives thereof of companies mentioned herein and may from time to time add to or dispose of any such securities (or investment). We and our affiliates may act as market makers or assume an underwriting commitment in the securities of companies discussed in this document (or in related investments), may sell them to or buy them from customers on a principal basis, and may also perform or seek to perform investment banking or advisory services for or relating to these companies and may also be represented in the supervisory board or any other committee of these companies.

For the purpose of calculating whether BOBCAPS and its affiliates hold, beneficially own, or control, including the right to vote for directors, one per cent or more of the equity shares of the subject company, the holdings of the issuer of the research report is also included.

BOBCAPS and its non-US affiliates may, to the extent permissible under applicable laws, have acted on or used this research to the extent that it relates to non-US issuers, prior to or immediately following its publication. Foreign currency denominated securities are subject to fluctuations in exchange rates that could have an adverse effect on the value or price of or income derived from the investment. In addition, investors in securities such as ADRs, the value of which are influenced by foreign currencies, effectively assume currency risk. In addition, options involve risks and are not suitable for all investors. Please ensure that you have read and understood the Risk disclosure document before entering into any derivative transactions.

In the US, this material is only for Qualified Institutional Buyers as defined under rule 144(a) of the Securities Act, 1933. No part of this document may be distributed in Canada or used by private customers in the United Kingdom.

No part of this material may be (1) copied, photocopied, or duplicated in any form by any means or (2) redistributed without BOBCAPS's prior written consent.

#### Other disclosures

BOBCAPS does not have any financial interest in the subject company. BOBCAPS does not have actual/beneficial ownership of one per cent or more securities in the subject company at the end of the month immediately preceding the date of publication of this report.

BOBCAPS is not engaged in any market making activities for the subject company.

BOBCAPS or its associates may have material conflict of interest at the time of publication of this research report.

BOBCAPS's associates may have financial interest in the subject company. BOBCAPS's associates may hold actual / beneficial ownership of one per cent or more securities in the subject company at the end of the month immediately preceding the date of publication of this report.

BOBCAPS or its associates may have managed or co-managed a public offering of securities for the subject company or may have been mandated by the subject company for any other assignment in the past 12 months.

BOBCAPS may have received compensation from the subject company in the past 12 months. BOBCAPS may from time to time solicit or perform investment banking services for the subject company. BOBCAPS or its associates may have received compensation from the subject company in the past 12 months for services in respect of managing or co-managing public offerings, corporate finance, investment banking or merchant banking, brokerage services or other advisory services in a merger or specific transaction. BOBCAPS or its associates may have received compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company in the past 12 months.

EQUITY RESEARCH 14 September 2020